Holding vs Continuing GLP-1/GIP Agonists Before Upper Endoscopy: The OCULUS Randomized Clinical Trial - PubMed
5 hours ago
- #clinical trial
- #GLP-1 agonists
- #upper endoscopy
- The OCULUS trial compared the risk of clinically significant residual gastric volume (RGV) in patients who continued versus held GLP-1/GIP agonists before upper endoscopy.
- Continuing GLP-1/GIP agonists increased the risk of clinically significant RGV (25.0% vs. 3.1% in the hold group).
- The trial was terminated early due to the increased risk exceeding preestablished stopping boundaries.
- Clear liquids the day before the procedure may mitigate the risk of clinically significant RGV, regardless of GLP-1/GIP use.
- The study included 60 patients, with a median age of 62.5 years, and was conducted at two US tertiary referral centers.